On April 20th, Exelixis (EXEL) announced positive results from the Phase 3 trial, CheckMate-9ER, evaluating the combination of Opdivo (nivolumab) and Cabometyx (cabozantinib) for the first-line treatment of advanced/metastatic renal cell carcinoma ("RCC"). The stock increased by roughly 40% in the days following the news release. Thereafter, it has taken a breather as investors took profits. In fact, the share price has increased by 77% from its March low at $14.46. Altogether, the stock appreciated over 36% since my previous recommendation. Don't shoot the messenger. You should listen to the message.
I'm not trying